top of page
Sphere on Spiral Stairs

Basilea Pharmaceutica

H1 2023 Results

Dr Brian White

Andrew Keith


15 August 2023

Screenshot 2023-08-15 at 11.19.11.png
Screenshot 2023-08-15 at 11.35.08.png

Results reflect Cresemba's dominance


Continued growth of the Cresemba franchise, along with a planned reduction in R&D spending, has taken Basilea into a period of sustained profitability and positive cash flow generation. Basilea’s H1 reflected a particularly strong performance with revenues of CHF84.9m and net profit of CHF31.8m resulting in an increased cash (including restricted cash) position of CHF112.9m. As a result, Basilea has modestly increased FY’23 guidance to total revenues of CHF147m-150m (from CHF145m-148m) and net profit to CHF41m-46m (from CHF36m-41m). Basilea has used this period of strong cash generation to pay down its senior secured loan, expecting that this will amount to CHF37m in FY23.


Cresemba's growth remains impressive


Cresemba continues to deliver growth above expectations with strong sales in established markets such as the US (through Astellas), and new important markets coming on stream. In H1 2023, we note the receipt of several milestone payments from outside the US, including a significant $26.25m receipt from Pfizer. The underlying performance of Cresemba was reflected in a highly creditable 27% increase in royalty income to CHF36.7m. End market Cresemba sales for the 12 months ended March 2023 were $393m. We expect growth to continue in the medium term despite its maturity largely due to an increasing number of at-risk immunosuppressed patients combined with Cresemba’s differentiated profile (broad spectrum and benign safety profile).


The increasing importance of ceftobiprole


Sales of Zevtera remain modest, reflecting its lack of approval in the key US market. With the NDA now filed for a combination of bacteraemia, severe skin infection and community-acquired pneumonia caused by Staphylococcus aureus (including MRSA), we look forward to the attraction of a suitable commercial partner before approval. In particular, we believe ceftobiprole promises to be a significant treatment option as part of empiric therapy for patients with bacteraemia, given its coverage of Gram-positive and Gram-negative infections and the lack of treatment options (particularly where resistance is suspected). Our forecasts suggest that peak sales in the US alone could approach $400m. Basilea is in a very strong financial position, and with that in mind, we expect any commercial agreement to maximise the long-term value of the ceftobiprole franchise. Securing a commercial partner able to maximise the sales potential of ceftobiprole in the key US market would represent a significant de-risking event, we believe.


Plans to augment the anti-infectives franchise


With the renewed emphasis on the anti-infectives franchise, the approval of ceftobiprole in the US will be an important event to secure its future. At the same time, we expect the company to augment the key-anti-fungal franchise ahead of the expiration of exclusivity in key markets in 2027. We expect Basilea to renew its efforts to in-license novel anti-fungals to ensure the longevity of the franchise and believe that the company’s in-house expertise should be a strong attraction for potential licensors. We note management’s commentary today regarding discussions about acquiring or in-licensing novel anti-infective candidates, providing reassurance that plans are well underway. Hopefully, the company’s strong cash position and existing anti-infectives franchise should help in this regard. We believe that providing visibility on the future anti-fungal pipeline would represent another important de-risking event for Basilea.


Our forecasts are currently under review


Calvine Partners LLP is authorised and regulated by the Financial Conduct Authority in respect of UK investment advisory and arranging activities.


This publication has been commissioned and paid for by Basilea Pharmaceutica and as defined by the FCA is not independent research. This report is considered to be a marketing communication under FCA rules, and it has not been prepared under the laws and requirements established to promote the independence of investment research, and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. The information provided is widely available to the public.


This report in the United Kingdom is directed at investment professionals, certified high net worth individuals, high net worth entities, self-certified sophisticated investors, eligible counterparties as defined by Financial Services and Markets Act 2000 (Financial Promotion) Order 2000. The report may also be distributed and made available to persons to whom Calvine Partners is lawfully permitted. This publication is not intended for use by any individual or entity in any jurisdiction or country where that use would breach law or regulations, or which would subject Calvine Partners or its affiliates to any registration requirement within such jurisdiction or country.


Calvine Partners may provide, or seek to provide, services to other companies mentioned in this report. Partners, employees, or related parties thereof may hold positions in the companies mentioned in the report subject to Calvine Partners’ personal account dealing rules.


Calvine Partners has only used publicly available information believed to be reliable at the time of this publication and made best efforts to ensure that the facts and opinions stated are fair, accurate, timely and complete at the publication date. However, Calvine Partners provides no guarantee concerning the accuracy or completeness of the report or the information or opinions within. This publication is not intended to be an investment recommendation, personal or otherwise, and it is not intended to be advice and should not be treated in any way as such. Any valuation estimates, such as those derived from a discounted cash flow, price multiple, or peer group comparison, do not represent estimates or forecasts of a future company share price. In no circumstances should the report be relied on or acted upon by non-qualified individuals. Personal or otherwise, it is not intended to be advice and should not be relied on in any way as such. 


Forward-looking statements, information, estimates and assumptions contained in this report are not yet known, and uncertainties may cause the actual results, performance or achievements to be significantly different from expectations.


This report does not constitute an offer, invitation or inducement to engage in a purchase or sale of any securities in the companies mention. The information provided is for educational purposes only and this publication should not be relied upon when making any investment decision or entering any commercial contract. Past performance of any security mentioned is not a reliable indicator of future results and readers should seek appropriate, independent advice before acting on any of the information contained herein. This report should not be considered as investment advice, and Calvine Partners will not be liable for any losses, costs or damages arising from the use of this report. The information provided in this report should not be considered in any circumstances as personalised advice.


Calvine Partners LLP, its affiliates, officers or employees, do not accept any liability or responsibility with regard to the information in this publication. None of the information or opinions in this publication has been independently verified. Information and opinions are subject to change after the publication of this report, possibly rendering them inaccurate and/or incomplete.


Any unauthorised copying, alteration, distribution, transmission, performance, or display, of this report, is prohibited.

bottom of page